About Climb Bio

Climb Bio is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. Our lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.